Haemonetics (NYSE:HAE) Issues Quarterly Earnings Results

Haemonetics (NYSE:HAE) released its quarterly earnings data on Thursday. The medical instruments supplier reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04, FiscalAI reports. The firm had revenue of $338.97 million during the quarter, compared to analysts’ expectations of $331.90 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.19 earnings per share. Haemonetics updated its FY 2026 guidance to 4.900-5.000 EPS.

Here are the key takeaways from Haemonetics’ conference call:

• Company raised full‑year guidance — reported revenue guidance tightened to a decline of ~1%–3%, organic revenue ex‑CSL raised to ~8%–10%, adjusted EPS now expected at $4.90–$5.00, and free cash flow guidance increased to $200–$220 million.
• Core product momentum — NexSys/TEG and Plasma drove outsized results (TEG adoption and a new heparinase cartridge accelerating conversions; Plasma organic growth ex‑CSL ~20% this quarter and ~22% YTD), with sustained share gains and innovation‑led pricing.
• Interventional Technologies (IVT) remains a drag — IVT revenue fell materially (down 12% Q/Q) due to esophageal cooling weakness, accelerated PFA adoption and OEM headwinds; management expects a turnaround in FY2027 but is investing now, so near‑term performance is challenged.
• Margins and cash generation strengthened — adjusted gross margin ~60%, operating‑margin guidance ~26%–27%, $74M free cash flow in the quarter (YTD $165M), cash balance up to $363M, active buybacks and the $61M Vivisure acquisition funded while keeping leverage manageable.

Haemonetics Trading Down 5.8%

Shares of NYSE HAE traded down $3.77 during midday trading on Friday, reaching $61.25. The stock had a trading volume of 534,204 shares, compared to its average volume of 864,546. Haemonetics has a twelve month low of $47.31 and a twelve month high of $87.32. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64. The company’s 50 day moving average price is $77.28 and its 200 day moving average price is $65.27. The firm has a market cap of $2.87 billion, a price-to-earnings ratio of 17.92, a price-to-earnings-growth ratio of 1.37 and a beta of 0.28.

Institutional Investors Weigh In On Haemonetics

Several institutional investors and hedge funds have recently made changes to their positions in HAE. AQR Capital Management LLC lifted its holdings in shares of Haemonetics by 372.8% in the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after purchasing an additional 1,678,630 shares in the last quarter. Millennium Management LLC lifted its position in Haemonetics by 4,296.3% in the 3rd quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock valued at $37,685,000 after acquiring an additional 755,592 shares in the last quarter. Balyasny Asset Management L.P. bought a new stake in Haemonetics during the 3rd quarter worth approximately $15,703,000. Qube Research & Technologies Ltd bought a new position in shares of Haemonetics in the third quarter valued at approximately $13,178,000. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Haemonetics during the third quarter worth $6,145,000. Institutional investors own 99.67% of the company’s stock.

Trending Headlines about Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Q3 EPS and revenue beat estimates and operating margins expanded, showing improved profitability versus the prior year. Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips
• Positive Sentiment: Management raised fiscal 2026 guidance and flagged an 8%–10% organic growth outlook driven by plasma and blood‑management businesses — a constructive forward indicator. Haemonetics raises fiscal 2026 guidance as plasma and blood management drive 8%-10% organic growth outlook
• Positive Sentiment: An analyst (BTIG) reaffirmed a Buy rating with an $88 price target, signaling continued sell‑side conviction that upside remains. Benzinga report on BTIG reaffirmation
• Neutral Sentiment: Market research/screening services highlight HAE as a top‑ranked growth stock (Zacks Style Scores), which may support medium‑term interest but is not an immediate catalyst. Haemonetics (HAE) is a Top-Ranked Growth Stock: Should You Buy?
• Neutral Sentiment: The company posted an earnings call transcript and slide deck — useful for longer‑horizon investors to parse segment drivers and cadence, but not an immediate market mover. Haemonetics HAE Q3 2026 Earnings Call Transcript
• Negative Sentiment: Revenue declined 2.7% year‑over‑year, signaling weaker demand in the quarter despite margin gains — a primary reason investors sold shares after the release. Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips
• Negative Sentiment: FY‑2026 EPS guidance (4.90–5.00) is roughly in line with consensus (~4.92); investors may have expected a bigger upside surprise, leaving sentiment muted. Official results and guidance were posted in the company release. PR Newswire: Haemonetics Announces Third Quarter Fiscal 2026 Financial Results

Analysts Set New Price Targets

A number of research analysts have issued reports on HAE shares. Mizuho decreased their target price on shares of Haemonetics from $90.00 to $80.00 and set an “outperform” rating on the stock in a research report on Friday. JPMorgan Chase & Co. boosted their price objective on shares of Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a research report on Friday, December 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haemonetics in a research note on Monday, December 29th. Needham & Company LLC lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, December 15th. Finally, Barrington Research set a $94.00 price objective on Haemonetics in a report on Friday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $83.50.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.